Neil Flanzraich
Executive Chairman

Mr. Flanzraich is the Executive Chairman of Tigris Pharmaceuticals. Also, Mr. Flanzraich is the Chairman of ParinGenix, Inc., another privately owned biotech company, which is developing a unique anti-inflammatory agent for a number of indications. Additionally, Mr. Flanzraich is a founder and a principal of a venture capital firm named Leviathan Biopharma Group, LLC.

Mr. Flanzraich was the Vice Chairman and President of Ivax Corporation, an international pharmaceutical company, that was sold to Teva in 2006 for $10 billion. Earlier he was the Senior Vice President and Chief Counsel and a member of the Executive Committee of Syntex Corporation, an international pharmaceutical company, that was sold to Roche in 1994 for $5.3 billion. He was also the Chairman of North American Vaccine, Inc., that was sold in 2000 to Baxter International, Inc. for about $500 million.

Currently, Mr. Flanzraich is also member of the boards of directors of the following public companies: Bellus Health Inc., Chipotle Mexican Grill, Continucare Corporation, and Equity One, Inc. Additionally, he is a member of the Board of Directors of privately-owned Outcomes Health Information Solutions, LLC, a provider of healthcare data retrieval, analytics and management services. Mr. Flanzraich is also a member of the Advisory Board of The Wolfsonian-FIU, a museum of art, design and communication.

Mr. Flanzraich graduated from Harvard College (magna cum laude, Phi Beta Kappa) and from Harvard Law School (magna cum laude). He is married and has two sons.

Edmundo Muniz, M.D., Ph.D.
President and Chief Executive Officer

Dr. Muniz brings over a decade of drug development experience in oncology and infectious disease. Prior to joining Tigris, Dr. Muniz was Vice President for Lilly Research Laboratories Global Oncology Platform at Eli Lilly and Company. At Lilly, Dr. Muniz was responsible for Phase II, III and IV clinical trials for oncology compounds worldwide and for Global Marketing Pre-launch.

Under Dr. Muniz's leadership, Lilly Oncology achieved 9 major oncology submissions worldwide, with 7 of those already having gained approval in the US or Europe. Such projects include Dr. Muniz's extensive involvement in the development of approved oncology therapeutics Alimta® and Gemzar®. Additionally, Dr. Muniz led the launch of Lilly Oncology on Canvas: Expressions of a Woman's Cancer Journey, an international art exhibition that displays works from over 400 cancer survivors, family members, care providers and friends. Prior to joining Eli Lilly, Dr. Muniz completed a residency in Preventive Medicine and a Fellowship in Epidemic Intelligence with the Centers for Disease Control and Prevention (CDC) in Atlanta.

Paul A. Mieyal, Ph.D., CFA
Director

Paul A. Mieyal, Ph.D., CFA is a Vice President of Wexford Capital LLC, an SEC registered investment advisor with over $5 billion of assets under management located in Greenwich, CT. Prior to that, he was Vice President in charge of healthcare investments for Wechsler & Co., Inc., a private investment firm and registered broker-dealer. Dr. Mieyal serves as a Director of Danube Pharmaceuticals, Inc., Epiphany Biosciences, Inc., Interventional Spine, Inc. and Microbiogen Pty Ltd. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.

Gregory F. Kiernan
Director

Greg Kiernan is the Managing Partner and founder of Sonostar Capital Partners, LLC an entrepreneurial investment fund established in 2005 and headquartered in Westchester, New York. He oversees all aspect's of the fund's investments and is the fund's largest investor, having provided 25% of the fund's investment capital. He is also the President and CEO and a founding partner of Sonostar Ventures, LLC, an investment and venture capital firm he established with David Moore in April 1997 that realized a nearly 13 times return on invested capital during its seven year life. Since the liquidation of that fund in 2005, Sonostar Ventures continues to operate as a firm providing consulting and advisory services to a range of clients.

Prior to founding Sonostar Ventures, Mr. Kiernan worked on Wall Street at Lehman Brothers, Salomon Brothers and then for 10 years at PaineWebber, where he was a Senior Managing Director in charge of the firm's institutional Corporate Bond, High Yield, Preferred Stock and Mortgage Backed Securities Departments. Mr. Kiernan served as a senior member of PaineWebber's Executive Operating Committee, as the Fixed Income representative on the firm's Risk Management Committee and as one of eight voting members on the firm's Commitment Committee. Until he left PaineWebber in 1997, Mr. Kiernan served as a Director on the Executive Committee of the Public Securities Association. Before starting his Wall Street career, Mr. Kiernan worked for Cravath, Swaine and Moore as an attorney admitted to practice law in New York State. Mr. Kiernan holds a J.D. degree from Harvard Law School and a B.A. from Amherst College, magna cum laude, Phi Beta Kappa.

Mr. Kiernan serves as a board member or advisory board member on a number of the companies in which Sonostar invests. In addition, he is a former board president and currently a director and vice president of Baypoint Navigation Corp., a Fire Island ferry service. He serves on the Executive Committee and Board of Directors of the Newburgh San Miguel School, where he chairs the fundraising and marketing committees. He is also a Director of the Newburgh San Miguel Program. He is a Canterbury School alumni class agent, past chairman of the Amherst College 25th Reunion Gifts Committee (and recipient of the Amherst College Alumni Distinguished Service Award ), a member of the Fairfield University Parents' Committee and a member of various other charitable ventures.

He resides in Chappaqua, New York with his wife, Vera and their five children.

Joshua A. Kazam
Secretary and Director

Mr. Kazam, a co-founder of Tigris, currently serves as the Secretary and a member of the Board of Directors of the Company. Mr. Kazam co-founded Two River Group Holdings, LLC in September 2004.

Prior to that, from September 1999, Mr. Kazam served as a Managing Director of Paramount BioCapital, Inc. He also served as Managing Director of Paramount BioCapital Investments, LLC, where he was responsible for ongoing operations of venture investments. In addition, Mr. Kazam served as the Director of Investment for the Orion Biomedical Fund, a New York based private equity fund focused on biotechnology investments. Mr. Kazam also currently serves as a director of Manhattan Pharmaceuticals, Inc. (AMEX:MHA), a publicly traded biotechnology company, as well as several privately held companies, including Cortiva Therapy and Velcera Pharmaceuticals, Inc., a privately held veterinary company.

Mr. Kazam graduated with honors from the Wharton School of the University of Pennsylvania with a degree in management. Mr. Kazam will devote only a portion of his business time to the Company's business.

Peter M. Kash
Director

Peter M. Kash has served as a director of the Company since its inception. In September 2004, Mr. Kash co-founded Two River Group Holdings, LLC, a venture capital firm that specializes in the creation of new companies to acquire rights to commercially develop early stage biotechnology products. He serves as President of Two River Group Management, LLC, the managing member of Two River Group Holdings, LLC. Mr. Kash is also the President and Chairman of Riverbank Capital Securities, Inc., a broker-dealer registered with the Financial Industry Regulatory Authority, or FINRA (formerly NASD). From 1992 until 2004, Mr. Kash was a Senior Managing Director of Paramount BioCapital, Inc., a FINRA member broker-dealer, specializing in conducting private financings for public and private development stage biotechnology companies as well as Paramount BioCapital Investments, LLC, a venture capital company. Mr. Kash also served as Director of Paramount Capital Asset Management, Inc., the general partner of several biotechnology-related hedge funds and as member of the General Partner of the Orion Biomedical Fund, LP, a private equity fund. Mr. Kash received his B.S. in Management Science from SUNY Binghamton and his M.B.A. in Banking and International Finance from Pace University. Mr. Kash is currently completing his doctorate in education at Yeshiva University.

Mark Pruzanski, M.D.
Observer

Dr. Pruzanski is a co-founder and member of the Board of Directors of the Company. Dr. Pruzanski is currently the CEO of Intercept Pharmaceuticals, a New York based biotechnology company he founded in 2003 to develop drugs for chronic liver and metabolic diseases. Dr. Pruzanski has over 12 years of experience in life sciences startup management and venture capital, strategy consulting and healthcare policy. He was previously a Venture Partner at Apple Tree Partners (ATP), an early stage life sciences venture capital firm he founded in 1999, where he worked with several portfolio companies to assist them in financing, strategic positioning and operations. Prior to that he was at Oak Investment Partners in Connecticut as an Entrepreneur in Residence with a focus on sourcing technology and startup company origination. Dr. Pruzanski is a Canadian physician who received his M.D. from McMaster University in Ontario, an M.A. degree in International Affairs from the Johns Hopkins School of Advanced International Studies in Bologna, Italy and Washington, DC, and a bachelor's degree from McGill University in Montreal, Quebec.